A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Hyzetimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Zhejiang Hisun Pharmaceutical
- 05 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 18 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 21 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.